Proteins at the intersection of circadian rhythms and metabolic dysfunction-associated steatotic liver disease: an 18-protein panel as a novel predictive biomarker set - Top-Institutions - MDSpire

Proteins at the intersection of circadian rhythms and metabolic dysfunction-associated steatotic liver disease: an 18-protein panel as a novel predictive biomarker set

  • By

  • Yiyi Wang

  • Qilong Zhai

  • Xuemei Lian

  • Lei Zhao

  • May 13, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    UK Biobank
    UK Biobank

    Cambridge, UK

    Key Differentiators

    • Biomedical Research

  • #2

    Baylor College of Medicine
    Baylor College of Medicine

    Houston, TX

    Key Differentiators

    • Hepatology
    • Medicine

  • #3

    Tokyo Women’s Medical University
    Tokyo Women’s Medical University

    Tokyo, Japan

    Key Differentiators

    • Hepatology

  • #4

    Hospital Universitari i Politècnic La Fe
    Hospital Universitari i Politècnic La Fe

    Valencia, Spain

    Key Differentiators

    • Hepatology

  • #5

    University of Navarra
    University of Navarra

    Pamplona, Spain

    Key Differentiators

    • Hepatology

Original Source(s)

Proteins at the intersection of circadian rhythms and metabolic dysfunction-associated steatotic liver disease: an 18-protein panel as a novel predictive biomarker set

  • by Yiyi Wang, Qilong Zhai, Xuemei Lian, Lei Zhao

  • May 13, 2026

Related Content

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants

Dietary patterns in young patients with lung cancer suggest that many have higher dietary quality scores than average U.S. reference values, according to results from a study presented at the American...

Unique Phase I NSCLC Trial Sites Decreasing in United States

The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant conso...